Free Trial

Gyre Therapeutics (GYRE) Stock Price, News & Analysis

Gyre Therapeutics logo
$7.49 -0.32 (-4.10%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$7.76 +0.27 (+3.67%)
As of 07/11/2025 05:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Gyre Therapeutics Stock (NASDAQ:GYRE)

Key Stats

Today's Range
$7.46
$7.80
50-Day Range
$7.35
$11.50
52-Week Range
$6.11
$19.00
Volume
65,837 shs
Average Volume
129,894 shs
Market Capitalization
$702.25 million
P/E Ratio
374.69
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Buy

Company Overview

Gyre Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
5th Percentile Overall Score

GYRE MarketRank™: 

Gyre Therapeutics scored higher than 5% of companies evaluated by MarketBeat, and ranked 944th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Gyre Therapeutics is 374.69, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.92.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Gyre Therapeutics is 374.69, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.05.

  • Price to Book Value per Share Ratio

    Gyre Therapeutics has a P/B Ratio of 7.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Gyre Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    11.07% of the float of Gyre Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Gyre Therapeutics has a short interest ratio ("days to cover") of 7.7.
  • Change versus previous month

    Short interest in Gyre Therapeutics has recently increased by 27.66%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Gyre Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Gyre Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.07% of the float of Gyre Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Gyre Therapeutics has a short interest ratio ("days to cover") of 7.7.
  • Change versus previous month

    Short interest in Gyre Therapeutics has recently increased by 27.66%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Gyre Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.00 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Gyre Therapeutics this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    1 people have added Gyre Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Gyre Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $23,804.00 in company stock.

  • Percentage Held by Insiders

    Only 10.00% of the stock of Gyre Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 23.99% of the stock of Gyre Therapeutics is held by institutions.

  • Read more about Gyre Therapeutics' insider trading history.
Receive GYRE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gyre Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GYRE Stock News Headlines

Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
See More Headlines

GYRE Stock Analysis - Frequently Asked Questions

Gyre Therapeutics' stock was trading at $12.10 at the beginning of the year. Since then, GYRE stock has decreased by 38.1% and is now trading at $7.49.

Gyre Therapeutics, Inc. (NASDAQ:GYRE) announced its quarterly earnings results on Friday, May, 9th. The company reported $0.03 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.03. The firm had revenue of $22.06 million for the quarter, compared to analyst estimates of $28.40 million. Gyre Therapeutics had a net margin of 7.20% and a trailing twelve-month return on equity of 9.73%.

Shares of GYRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Gyre Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Palo Alto Networks (PANW) and Invesco QQQ (QQQ).

Company Calendar

Last Earnings
5/09/2025
Today
7/12/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GYRE
Previous Symbol
NASDAQ:GYRE
CIK
1124105
Employees
40
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
$0.02
Trailing P/E Ratio
374.69
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$12.09 million
Net Margins
7.20%
Pretax Margin
15.27%
Return on Equity
9.73%
Return on Assets
7.66%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.60
Quick Ratio
3.19

Sales & Book Value

Annual Sales
$105.76 million
Price / Sales
6.64
Cash Flow
$0.19 per share
Price / Cash Flow
39.54
Book Value
$1.05 per share
Price / Book
7.13

Miscellaneous

Outstanding Shares
93,760,000
Free Float
84,382,000
Market Cap
$702.26 million
Optionable
No Data
Beta
1.72
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:GYRE) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners